Supplementary Figure 1 from Evolving Information Needs among Colon, Breast, and Prostate Cancer Survivors: Results from a Longitudinal Mixed-Effects Analysis

Andy S.L. Tan(Boston University), Angela DeMichele(University of Pennsylvania), Robert Hornik(University of Pennsylvania), Rebekah H. Nagler(University of Minnesota)

Unknown

March 31, 2023

10.1158/1055-9965.22436220

Cited by 0

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Association Between Initial Use of e-Cigarettes and Subsequent Cigarette Smoking Among Adolescents and Young Adults

|JAMA Pediatrics|2017|1.2k

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

|JAMA Oncology|2020|707

Prediction and change of health behavior: Applying the reasoned action approach.

|Unknown|2007|498